Patents by Inventor Michael Scott Visser

Michael Scott Visser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20230067476
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 2, 2023
    Inventors: Claire ADCOCK, Simone BONAZZI, Artiom CERNIJENKO, Philip LAM, Kathryn Taylor LINKENS, Hasnain Ahmed MALIK, Noel Marie-France THOMSEN, Michael Scott VISSER
  • Protein kinase C inhibitors and methods of their use
    Patent number: 11505541
    Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: November 22, 2022
    Assignee: Novartis AG
    Inventors: Michael Joseph Luzzio, Julien Papillon, Michael Scott Visser
  • PROTEIN KINASE C INHIBITORS FOR TREATMENT OF UVEAL MELANOMA
    Publication number: 20220323436
    Abstract: The present disclosure relates to use of a protein kinase C (PKC) inhibitor in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, and related disclosure embodiments. The disclosure further relates to use of a pharmaceutical combination comprising a PKC inhibitor and another therapeutic agent, such as an MDM2 inhibitor, in the treatment or prevention of a proliferative disease.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 13, 2022
    Inventors: Vesselina Cooke, Michael Scott Visser, Andrew Wylie, Padmaja Yerramilli-Rao, Xu Zhu
  • Protein kinase C inhibitors for treatment of uveal melanoma
    Patent number: 11413284
    Abstract: The present disclosure relates to use of a protein kinase C (PKC) inhibitor in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, and related disclosure embodiments. The disclosure further relates to use of a pharmaceutical combination comprising a PKC inhibitor and another therapeutic agent, such as an MDM2 inhibitor, in the treatment or prevention of a proliferative disease.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: August 16, 2022
    Assignee: Novartis AG
    Inventors: Vesselina Cooke, Michael Scott Visser, Andrew Wylie, Padmaja Yerramilli-Rao, Xu Zhu
  • 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20220144807
    Abstract: The present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, R3, Rx, and n are as defined herein, and methods of making and using same.
    Type: Application
    Filed: February 13, 2020
    Publication date: May 12, 2022
    Inventors: Rohan Eric John BECKWITH, Simone BONAZZI, Artiom CERNIJENKO, Michael Scott VISSER
  • PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20210387962
    Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
    Type: Application
    Filed: March 12, 2021
    Publication date: December 16, 2021
    Inventors: Michael Joseph Luzzio, Julien Papillon, Michael Scott Visser
  • 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 11192877
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: December 7, 2021
    Assignee: Novartis AG
    Inventors: Claire Adcock, Simone Bonazzi, Artiom Cernijenko, Philip Lam, Kathryn Taylor Linkens, Hasnain Ahmed Malik, Noel Marie-France Thomsen, Michael Scott Visser
  • 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20210309638
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.
    Type: Application
    Filed: June 9, 2021
    Publication date: October 7, 2021
    Inventors: Rohan Eric John BECKWITH, Simone BONAZZI, Artiom CERNIJENKO, Aleem FAZAL, Ritesh Bhanudasji TICHKULE, Michael Scott VISSER
  • Protein kinase C inhibitors and methods of their use
    Patent number: 11059804
    Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: July 13, 2021
    Assignee: Novartis AG
    Inventors: Michael Joseph Luzzio, Julien Papillon, Michael Scott Visser
  • 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 11053218
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: July 6, 2021
    Inventors: Rohan Eric John Beckwith, Simone Bonazzi, Artiom Cernijenko, Aleem Fazal, Ritesh Bhanudasji Tichkule, Michael Scott Visser
  • PROTEIN KINASE C INHIBITORS FOR TREATMENT OF UVEAL MELANOMA
    Publication number: 20200268749
    Abstract: The present disclosure relates to use of a protein kinase C (PKC) inhibitor in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, and related disclosure embodiments. The disclosure further relates to use of a pharmaceutical combination comprising a PKC inhibitor and another therapeutic agent, such as an MDM2 inhibitor, in the treatment or prevention of a proliferative disease.
    Type: Application
    Filed: September 11, 2018
    Publication date: August 27, 2020
    Inventors: Vesselina COOKE, Michael Scott VISSER, Andrew WYLIE, Padmaja YERRAMILLI-RAO, Xu ZHU
  • PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20200262814
    Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
    Type: Application
    Filed: October 28, 2019
    Publication date: August 20, 2020
    Inventors: Michael Joseph Luzzio, Julien Papillon, Michael Scott Visser
  • 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20200231569
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.
    Type: Application
    Filed: March 31, 2020
    Publication date: July 23, 2020
    Inventors: Rohan Eric John BECKWITH, Simone BONAZZI, Artiom CERNIJENKO, Aleem FAZAL, Ritesh Bhanudasji TICHKULE, Michael Scott VISSER
  • 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 10647701
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: May 12, 2020
    Assignee: Novartis AG
    Inventors: Rohan Eric John Beckwith, Simone Bonazzi, Artiom Cernijenko, Ritesh Bhanudasji Tichkule, Michael Scott Visser
  • 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 10640489
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: May 5, 2020
    Assignee: Novartis AG
    Inventors: Rohan Eric John Beckwith, Simone Bonazzi, Artiom Cernijenko, Ritesh Bhanudasji Tichkule, Michael Scott Visser
  • 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20200017461
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.
    Type: Application
    Filed: July 8, 2019
    Publication date: January 16, 2020
    Inventors: Claire ADCOCK, Simone BONAZZI, Artiom CERNIJENKO, Philip LAM, Kathryn Taylor LINKENS, Hasnain Ahmed MALIK, Noel Marie-France THOMSEN, Michael Scott VISSER
  • Protein kinase C inhibitors and methods of their use
    Patent number: 10508101
    Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: December 17, 2019
    Assignee: NOVARTIS AG
    Inventors: Michael Joseph Luzzio, Julien Papillon, Michael Scott Visser
  • 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20190367483
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X2, n, n1, and q are as defined herein, and methods of making and using same.
    Type: Application
    Filed: August 5, 2019
    Publication date: December 5, 2019
    Inventors: Rohan Eric John BECKWITH, Simone BONAZZI, Artiom CERNIJENKO, Aleem FAZAL, Ritesh Bhanudasji TICHKULE, Michael Scott VISSER
  • 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20190359594
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.
    Type: Application
    Filed: August 5, 2019
    Publication date: November 28, 2019
    Inventors: Rohan Eric John BECKWITH, Simone BONAZZI, Artiom CERNIJENKO, Aleem FAZAL, Ritesh Bhanudasji TICHKULE, Michael Scott VISSER
  • 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 10414755
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 17, 2019
    Assignee: Novartis AG
    Inventors: Rohan Eric John Beckwith, Simone Bonazzi, Artiom Cernijenko, Aleem Fazal, Ritesh Bhanudasji Tichkule, Michael Scott Visser